Clinically Sufficient Vitamin D Levels With Survival and Cardiovascular Outcomes in a Prospective Cohort of 3,995 Individuals Diagnosed With Invasive Breast Cancer
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
BACKGROUND: Vitamin D deficiency is prevalent in patients with breast cancer. The existing body of literature links vitamin D to lower total cancer mortality, yet the evidence on cardiovascular health is mixed. As there have been no randomized clinical trials on vitamin D supplementation in patients with breast cancer, evidence from large prospective studies is valuable to inform recommendations for this patient population. PATIENTS AND METHODS: We measured serum 25-hydroxyvitamin D (25OHD) levels in 3,995 women with incident breast cancer in a prospective cohort, which were categorized based on clinical cut points and evaluated with cancer survival outcomes and incident cardiovascular events. RESULTS: The median follow-up was 12.2 (range, 0.2-16.3) years. Patients with sufficient versus deficient vitamin D levels had better overall survival (adjusted hazards ratio [HR], 0.76; 95% CI, 0.62-0.93; P for trend =.005), second primary cancer-free survival (HR, 0.75; 95% CI, 0.63-0.90; P for trend =.003), and disease-free survival (HR, 0.82; 95% CI, 0.70-0.97; P for trend =.05). The associations were stronger in patients with stage ≥II disease (P for interaction
Fields of Study & Subjects
Vitamin D Research Studies
Nutritional Studies and Diet
Global Cancer Incidence and Screening
Publication details
- Journal / source
- Journal of the National Comprehensive Cancer Network
- Volume
- 24
- Issue
- 4
- Publication date
- 30 March 2026
- Language
- EN